Novel Semi-Synthetic Cu (II)-Cardamonin Complex Exerts Potent Anticancer Activity against Triple-Negative Breast and Pancreatic Cancer Cells via Inhibition of the Akt Signaling Pathway

Cardamonin is a polyphenolic natural product that has been shown to possess cytotoxic activity against a variety of cancer cell lines. We previously reported the semi-synthesis of a novel Cu (II)-cardamonin complex ( ) that demonstrated potent antitumour activity. In this study, we further investiga...

Full description

Saved in:
Bibliographic Details
Published inMolecules (Basel, Switzerland) Vol. 26; no. 8; p. 2166
Main Authors Hossan, Md Shahadat, Break, Mohammed Khaled Bin, Bradshaw, Tracey D, Collins, Hilary M, Wiart, Christophe, Khoo, Teng-Jin, Alafnan, Ahmed
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 09.04.2021
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cardamonin is a polyphenolic natural product that has been shown to possess cytotoxic activity against a variety of cancer cell lines. We previously reported the semi-synthesis of a novel Cu (II)-cardamonin complex ( ) that demonstrated potent antitumour activity. In this study, we further investigated the bioactivity of against MDA-MB-468 and PANC-1 cancer cells in an attempt to discover an effective treatment for triple-negative breast cancer (TNBC) and pancreatic cancer, respectively. Results revealed that abolished the formation of MDA-MB-468 and PANC-1 colonies, exerted growth-inhibitory activity, and inhibited cancer cell migration. Further mechanistic studies showed that induced DNA damage resulting in gap 2 (G2)/mitosis (M) phase arrest and microtubule network disruption. Moreover, generated reactive oxygen species (ROS) that may contribute to induction of apoptosis, corroborated by activation of caspase-3/7, PARP cleavage, and downregulation of Mcl-1. Complex also decreased the expression levels of p-Akt and p-4EBP1, which indicates that the compound exerts its activity, at least in part, via inhibition of Akt signalling. Furthermore, decreased the expression of c-Myc in PANC-1 cells only, which suggests that it may exert its bioactivity via multiple mechanisms of action. These results demonstrate the potential of as a therapeutic agent for TNBC and pancreatic cancer.
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules26082166